CCHT's subsidiary has received approval for the clinical trial application for the domestic production of the injectable GenSci143 drug
I'm PortAI, I can summarize articles.
CCHT's subsidiary Changchun Jinsai Pharmaceutical recently received approval from the National Medical Products Administration to conduct clinical trials for the injectable GenSci143. This drug is a Class 1 biological product primarily used for the treatment of advanced solid tumors such as prostate cancer and lung cancer, with dual potential for targeted chemotherapy and tumor immunotherapy, aimed at overcoming tumor heterogeneity and resistance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments